



IDH Results Presentation

September 2021





Contents:

- IDH At a Glance
- 1H 2021 Results Overview
- Key Investment Highlights
 - Our Market
 - Our Business Model
 - Financial Position and Performance
 - Growth Strategies
 - Governance

Who We Are

Integrated Diagnostics Holding is a leading, fully-integrated provider of high-quality medical diagnostic services with a footprint spanning Egypt, Jordan, Sudan and Nigeria

Our Services

Immunology	Radiology	Hematology
Endocrinology	Clinical Chemistry	Molecular Biology
Cytogenetics	Histopathology	Microbiology

Our Brands



Accreditations



+ 40 years
Track record

+2,000
Diagnostic tests
offered

7 key brands
With strong awareness


4
Country footprint (Egypt,
Jordan, Sudan & Nigeria)

495
Branch labs as at 30 June 2021

7.1 MN
FY20 Patients


27.1 MN
FY20 Tests

EGP **2.7** BN
FY20 Revenues



Our Geography

IDH's branch network of 495 labs as at 30 June 2021 spans 4 countries, the largest of which is Egypt



Our Patients

IDH serves two principal types of patients: contract and walk-in

Around 70% of total revenue generated across the two segments is paid in cash

Contract Patients


IDH's **contract clients** include institutions who enter into **one-year renewable contracts** at agreed rates per-test and on a per-client basis. Around 40% of the revenue generated by the segment is paid in cash. IDH's corporate clients roster currently features institutions such as:

- Unions
- Syndicates
- Private and public insurance companies
- Banks and corporations
- Public institutions


Walk-In Patients


IDH's walk-in clients, also referred to as "self-payers", **pay out of pocket** for diagnostic tests and other services.

Contribution to IDH Revenue (1H 2021)



Patient Split by Segment (1H 2021)





1H 2021 Results Overview

Results Snapshot

IDH recorded exceptional growth with impressive margin expansions at all levels of profitability in 1H 2021

EGP 2,293 mn

Revenue in 1H 2021

▲ 141% y-o-y

EGP 1,305 mn

Gross Profit in 1H 2021

▲ 193% y-o-y / 57% margin

EGP 1,203 mn

EBITDA in 1H 2021

▲ 227% y-o-y / 52% margin

EGP 668 mn

Net Profit in 1H 2021

▲ 283% y-o-y / 29% margin

16.3 mn

Tests completed in 1H 2021

▲ 45% y-o-y

4.7 mn

Patients served in 1H 2021

▲ 62% y-o-y

EGP 141

Average revenue per test in 1H 2021


▲ 66% y-o-y
(▲ 7% y-o-y ex-Covid-19-related testing)

495

Operational branch labs
as at 30 June 2021

▲ 33 branches vs. 30 June 2020

Revenue Breakup 1H 2021




*Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other Covid-19-related tests which include a bundle of routine inflammatory and clotting markers (which witnessed strong demand following the outbreak of Covid-19) such as Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), among others.

Record-breaking Top-line Growth in 1Q 2021

IDH continued to build on a strong start to the year delivering record-breaking top-line growth in 1H 2021 supported by both its Covid-19-related* tests and a sustained recovery in the Group's conventional test offering


IDH Revenues | EGP mn

Consolidated revenue growth in 1H 2021 was both volume- and price-driven. Revenue generated by IDH's conventional test offering recorded a robust 38% y-o-y rise in 1H 2021.




IDH Average Revenue per Test | EGP

Average revenue per test increased by 66% y-o-y on the back of the generally higher-priced Covid-19-related tests. Revenue per conventional test expanded 7% y-o-y in the period.




IDH Patient Volumes | '000

IDH served 62% more patients in the first half of 2021 compared to the same period of last year thanks to an expanded service offering and delivery capabilities.



IDH Test Volumes | '000

Total tests performed increased 45% y-o-y supported by both IDH's Covid-19-related tests as well as its conventional test offering, with the latter increasing by 29% versus last year.




*Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other Covid-19-related tests which include a bundle of routine inflammatory and clotting markers (which witnessed strong demand following the outbreak of Covid-19) such as Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), among others.

Strong Group Profitability in 1H 2021

Strong consolidated revenue growth and the dilution of fixed costs for the period saw IDH deliver remarkable growth with margin enhancements at all levels of profitability in 1H 2021


IDH COGS Breakdown | EGP mn / % of Revenue

As a percentage of sales, IDH's cost of goods sold decreased to 43.1% in 1H 2021 from 53.0% last year. This comes on the back of the dilution of several fixed cost items during the period.




IDH Consolidated Gross Profit | EGP mn / %

Strong top-line growth supported a 193% year-on-year expansion in gross profit to EGP 1,305 million for the six-month period, with an associated margin of 57% versus 47% last year.




IDH SG&A Breakdown | EGP mn / % of Revenue

SG&A/sales stood at 9.2% versus 17.8% in 1H 2020. It is worth noting that provisions booked for expected credit losses declined to EGP 10 million in 1H 2021 from EGP 28 million last year.



IDH Normalised EBITDA* | EGP mn

Normalised EBITDA growth in 1H 2021 came on the back of strong top-line growth and the dilution of fixed costs. Growth was further bolstered by the normalisation of provisions booked during the period.




*Normalised EBITDA is calculated as operating profit plus depreciation and amortization and minus one-off fees incurred in 1H 2021 related to the Company's EGX listing completed in May 2021..

Impressive Bottom-line Growth in 1H 2021

Improving net profitability was supported by strong revenue growth coupled with increased cost efficiencies, higher interest income and normalising provisions for the period


IDH Interest Expenses | EGP mn / % of Revenue

The increase in largely attributable to **higher interest expenses on borrowings** incurred by IDH coupled with **higher bank charges** resulting from increased penetration and reliance on POS machines and electronic payments during the period.




IDH Taxes | EGP mn / % of Revenue

IDH's effective tax rate stood unchanged at 35% in 1H2021 versus the comparable six-month period of last year.



IDH Consolidated Net Profit | EGP mn / %

Net Profit expanded 283% year-on-year to record EGP 668 million in 1H 2021, with a net profit margin of 29% versus 18% in 1H 2020. Net profit growth was supported by strong EBITDA level profitability and comes despite IDH booking EGP 29 million in one-off fees related to the Company's dual-listing in May 2021.




Solid Financial Position

The Group maintains a robust financial position, with a liquid balance sheet thanks to a strong cash generation profile allowing for consistent dividend payouts


Consolidated Cash Balance[^] | EGP mn

IDH's cash balances increased to EGP 1,587 million as at 30 June 2021 compared to EGP 877 million as at 31 December 2020.




Net Cash Balance^{*} | EGP mn

Net cash balance amounted to EGP 904[^] million as at 30 June 2021, an increase of 181% compared to EGP 321 million as at 31 December 2020.




Net Cash Flow from Operating Activities | EGP mn

Net cash flow from operating activities recorded EGP 866 million in 1H 2021 compared to EGP 149 million in 1H 2020, demonstrating the company's continued strong cash generation ability.



Dividend, Dividend per Share | US\$ mn, US\$

A dividend of US\$ 29.1 million (US\$ 0.0485 per share) for the year ended 31 December 2020 was distributed to shareholders on 29 July 2021. This represents an increase of 4% compared to a final dividend of US\$ 28 million in aggregate in the previous financial year.




^{*}Net cash is calculated as cash and cash equivalent balances less interest-bearing debt (medium term loans) and finance lease.

[^]The consolidated cash balance and net cash balance figures as at 30 June 2021 do not include dividend payments of US\$ 29.1 million distributed to shareholders on 29 July 2021.

^{^^}Based on 600 million shares.

Sustained Quarter-on-Quarter Growth

The Group's 1H 2021 performance was buoyed by an impressive second quarter, which saw IDH build on the strong momentum from the start of the year to record another set of record-breaking quarterly results



*2Q 2021 figure reflects IDH's normalized EBITDA which factors out one-off fees totaling EGP 29 million related to IDH's dual listing on the EGX.

** 2Q 2021 figure includes EGP 29 million in one-off fees related to IDH's dual listing as well as EGP 12.5 million in transaction fees related to its newly secured IFC loan.

Segment Performance

Both IDH's contract and walk-in segments recorded strong volume and revenue growth in the first six months of the year supported by conventional and Covid-19-related* tests

	Walk-In Segment			Contract Segment			Total		
	1H 2020	1H 2021	Change	1H 2020	1H 2021	Change	1H 2020	1H 2021	Change
Revenue^ (EGP mn)	443	1,029	132%	507	1,264	149%	950	2,293	141%
Covid-19-related revenue (EGP mn)	41	506		47	598		88	1,105	
Patients ('000)	943	1,523	62%	1,947	3,150	62%	2,890	4,673	62%
% of Patients	33%	33%		67%	67%				
Revenue per Patient (EGP)	470	676	44%	260	401	54%	329	491	49%
Tests ('000)	3,063	4,164	36%	8,171	12,153	49%	11,234	16,318	45%
% of Tests	27%	26%		73%	74%				
Covid-19-related tests ('000)	161	758	372%	417	1,842	342%	577	2,600	350%
Revenue per Test (EGP)	145	247	71%	62	104	68%	85	141	66%
Test per Patient	3.3	2.7	-16%	4.2	3.9	-8%	3.9	3.5	-10%

12.2 mn

Contract tests
in 1H 2021

▲ 49% y-o-y

▲ 33% y-o-y excluding
Covid-19-related tests

EGP 104

Avg. rev / contract test
in 1H 2021

▲ 68% y-o-y

▲ 9% y-o-y excluding
Covid-19-related tests

EGP 1,264 mn

Contract revenue
in 1H 2021

▲ 149% y-o-y

▲ 45% y-o-y excluding
Covid-19-related tests

4.2 mn

Walk-in tests
in 1H 2021

▲ 36% y-o-y

▲ 17% y-o-y excluding
Covid-19-related tests

EGP 247

Avg. rev / walk-in test
in 1H 2021

▲ 71% y-o-y

▲ 11% y-o-y excluding
Covid-19-related tests

EGP 1,029 mn

Contract revenue
in 1H 2021

▲ 132% y-o-y

▲ 30% y-o-y excluding
Covid-19-related tests

*Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other Covid-19-related tests which include a bundle of routine inflammatory and clotting markers (which witnessed strong demand following the outbreak of Covid-19) such as Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), among others.


^2020 and 2021 figures include Wayak's results.

Segment Performance

The contract segment continued to contribute the lion share of both patient volumes and consolidated revenues in 1H 2021


Revenue Split

1H 2020



■ Walk-in ■ Corporate


1H 2021



■ Walk-in ■ Corporate


Patient Split

1H 2020



■ Walk-in ■ Corporate


1H 2021



■ Walk-in ■ Corporate

Regional Performance

IDH witnessed strong results from its operations in Egypt, Jordan and Nigeria, with its Sudanese operations impacted from the sharp devaluation of the Sudanese pound in February




SDG = 0.1225 EGP, JOD = 22.0440 EGP, and NGN = 0.0412 EGP


COVID-19-adapted Service Offering

Top-line growth in Egypt and Jordan was supported by IDH's Covid-19-related* test offering and its ramped-up house call service, both of which continue to witness strong demand in both countries


Covid-19 Testing Contribution to IDH Revenue 1H21




House Call Contribution to IDH Revenue 1H21




EGYPT




JORDAN



EGYPT



JORDAN



* Covid-19-related tests include both Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other Covid-19-related tests which include a bundle of routine inflammatory and clotting markers such as Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), among others..

** Includes EGP 32 million contributed from PCR testing conducted as part of IDH's agreement with Pure Health.

Continued Ramp up at Al Borg Scan



Al Borg Scan offers a full range of radiology services, including but not limited to Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound, X-ray and Mammograms.

EGP 19.9 MN

1H 2021 Revenue
+124% vs 1Q20

EGP 3.1 MN
(16% margin)

1H 2021 EBITDA
vs EGP 0.4 mn in 1H20


EGP 579

1H 2021
Revenue/Test


EGP 721

1H 2021
Revenue/Patient


Revenue | EGP mn




EBITDA | EGP mn



Patients Served | k



Test Performed | k



IDH's Al-Borg Scan recorded robust revenue growth during the first half of 2021, with its top-line expanding to EGP 20 million, a 124% year-on-year rise. This came on the back of a 103% increase in the total number of radiology tests performed, coupled with a 10% increase in average revenue per test following the introduction of the higher-priced PET-CT scan in late 2020.



Investment Highlights

Investment Highlights

IDH is an attractive investment opportunity with compelling fundamentals, present in fast-growing, under-served markets



1	Operating in highly fragmented markets characterised by strong structural growth drivers and high barriers to entry	
2	Deploys an asset-light business model that allows for quick, capital-efficient growth helping to strengthen IDH's brand equity and market leading position	
3	Strong historical growth with attractive margins, an unlevered balance sheet, and strong cash generation ability allowing for consistently high dividend distribution	
4	Allowing for capitalization on multiple future growth avenues	
5	Supported by a world-class management and board of directors with robust governance frameworks	

Fast-Growing, Underserved Markets




Favorable Industry Dynamics

IDH's home market of Egypt is underpinned by robust structural growth drivers

Operating in a still under-penetrated market

Healthcare expenditures-per-capita and lab tests-per-capita demonstrate the underpenetrated nature of the IDH's markets.




Source: Analysis of the US Clinical Laboratory Market; Frost & Sullivan – March 2012 – NHS UK

Large Populations


At just over 100 million, Egypt is the third most populous country in Africa and by far the most populous country in the Middle East.

Top 5 African and Middle Eastern Country Populations

African Populations 2020 (in millions)



Middle Eastern Populations 2020 (in millions)



Source: World Bank

*CAPMAS (Central Agency for Public Mobilization and Statistics) announced that Egypt's population had surpassed the 100 million in February 2020.

High Disease Burden

The Egyptian population is marked by a high incidence of lifestyle-related medical conditions, with obesity being a notable example given its high correlation with many life-threatening illnesses including cardiovascular disease, diabetes and cancer.

35%

Adult Egyptian population that is obese

10%

Egyptian children who are considerably overweight

28%

Heart disease, the leading cause of death, highly correlated with obesity


Heightened Health Consciousness

A growing consumer class is, however, becoming more health and wellness conscious.



Favorable Industry Dynamics

IDH's markets are characterised by high barriers to entry



Economies of Scale

IT-enabled platform, critical mass (higher margins), decades of know-how and cutting-edge equipment mitigate against new entrants



Accreditation of Facilities

Attracting patients requires accredited, high-quality testing capabilities



Brand & Reputation

Patients are loyal to brands with a long track record for safety and quality



Market Reach

Fragmented markets necessitate a far-reaching network of branches to serve population effectively




Key Stakeholder Relationships

Building a scalable platform requires strong relationships with all stakeholders – from key suppliers to the Ministry of Health

IDH is a Consumer-Facing Service Provider

The mechanics of healthcare markets in developing economies are markedly different from those in many Western healthcare industries

Private Healthcare Systems in Developing Economies



Scalable Business Model



Asset-light Business Model

IDH's "Hub, Spoke and Spike" business model enables the Company to organically expand its reach in highly-fragmented markets with underserved diagnostic services demand

Mega Lab: "Hub"


- The Mega Lab, the largest automated lab in Egypt, serves as IDH's diagnostic "Hub," equipped with the latest technology to provide a full suite of diagnostic tests.
- Significant cost synergies are realized on kits, logistics and quality control.

B Labs: "Spokes"

- The B Labs serve as "Spokes" that reduce traffic to the Mega Lab by processing routine test on site including chemistry, parasitology and hematology.
- B Labs are both large in size and higher in capacity than the C Labs.
- At 30 June 2021, there were seven B Labs in Egypt and 21 in Jordan.

C Labs: "Spikes"

- The C Labs are collection centers, conducting the most basic of tests.
- Because they require low capital to open, they enable IDH to expand its reach in highly-fragmented markets.
- Typical C Labs take an average of three months to set up.



Our Mega Lab

IDH's Mega Lab provides a robust platform to support rapid, cost-effective growth

Capabilities

- Mega Lab machines are **capable of conducting a wide range of tests** including basic blood grouping to advanced gene sequencing.
- New and esoteric test facilities at the Mega **Lab allow IDH to offer over 2,000 diagnostic tests**, in turn helping to drive IDH's key test-per-patient metric.

Capacity

- Inauguration of IDH's Mega Lab in 2015 **doubled testing capacity to 20,000 tests per hour**.
- High capacity and capability for a broad range of tests provides IDH the ability to **plug and play for further expansion**.
- IDH's Mega Lab typically operates at just 55% of its maximum capacity leaving **ample room for further growth**.

Procurement

- Central procurement system ensures **coordinated purchasing across the Group**.
- IDH is in a good position to negotiate **favourable kit prices** and procure additional equipment to enhance capacity if required.
- IDH's centralised procurement model enables the company to **expand its operations in an efficient and cost-effective manner**.

Quality Control

- IDH adheres to the **highest quality standards**, with safety and testing procedures continuously enhanced.
- The centralisation resulting from Mega Lab allows IDH to maintain a **tight oversight on the quality** of its testing operations.
- IDH's **Mega Lab is the only CAP-accredited facility in Egypt**, demonstrating the excellence of IDH's patient care and confidence in the laboratory's practices.



Only CAP accredited laboratory in Egypt

Key Supplier Relationships

IDH leverages its bargaining power with suppliers to maximize value in a business that is fundamentally about economies of scale

Dynamics of Supplier Relationships

- IDH engages in re-agent deals whereby the majority of its **testing equipment is provided at no upfront payment** as part of a wider agreement to purchase a minimum volume of kits from the equipment supplier.
- These **contracts typically have tenors ranging from 5 to 7 years**, with the equipment substituted following the contract's renewal.
- Laboratory test **kits are purchased on contract with volume-linked pricing**.
- Significant volume and scale has also placed the Company in a **favorable position to negotiate test kit prices**, thus manage costs effectively, especially during recent challenging macroeconomic times.
- Supplier relationships **helped protect gross margins despite a >50% devaluation** of the EGP after the November 2016 float.

INTEGRATED DIAGNOSTICS HOLDINGS

biolab

Alborg
Laboratories

ECHO
LAB
RADIOLOGY &
LABORATORY
SERVICES



al mokhtabar
modernized clinical laboratories

Abbott
A Promise for Life

Roche

sysmex

SIEMENS

SUPPLIERS

Strong Growth and Financial Position




TOXICITY CRITERIA AND			
SITE	MEASURE	O/WNL	
LIVER	ALT	WNL	1 (0
	AST	WNL	=2.5
		WNL	=2.5
PANCREAS	4. 1. AL BILI	WNL	---
	5. LIV -CLIN	WNL	---
	1. Anyla	WNL	---
RENAL	2. Glucose	WNL	---
	1. Urea	WNL	<1.5 x
	2. Creatinir	WNL	6 -1
BONE	3. Blood P systolic	WNL	<1.5
	Pressure -	baseline	<10%
	5. Hema	ncg	±5%
			micro only


Key Financial Performance Indicators

Since the Company's IPO on the LSE in 2015, IDH has delivered consistent top- and bottom-line growth supported by a steady increase in volumes and increasingly favourable pricing across the Group's service offering


Revenue | EGP mn - CAGR




Gross Profit - GPM | EGP mn - % - CAGR




EBITDA - EBITDA Margin | EGP mn - % - CAGR




Net Profit - NPM | EGP mn - % - CAGR



Number of Tests | mn - CAGR




Number of Patients | mn - CAGR



Note: FY19 figures include Wayak & IFRS 16

Regional Performance

Across its footprint, the Company deploys tailored expansion strategies which enable it to continue driving growth irrespective of the prevailing macroeconomic environment



Growth Strategies



Future Growth Strategies

IDH's growth strategies rely on leveraging its competitive advantages to achieve four strategic goals

Expand Customer Reach

Beyond opening laboratories in new geographies, IDH is reaching out to new customers with focused tactical marketing activities as well as new customer services.

Increase Tests per Patient

While opening more branches will add both patients and tests, further diversifying the test portfolio in combination with compelling offerings of promotionally-priced test packages will drive the key financial metric of number of tests per patient.

Expand Geographically

In addition to organic expansion, the Company continues to seek value-accretive acquisitions in African and Middle Eastern markets where its business model is well-suited to capitalise on similar healthcare and consumer trends and capture significant share of fragmented markets.

Diversify into New Medical Services

The Group also looks to add diagnostic and medical services not currently provided on a large scale, believing its scale and experience position it well to take advantage of developing services opportunities that would raise the IDH profile to that of a "one-stop-shop" provider.

Expanding Customer Reach – IDH Awareness Campaigns

Parallel to state-sponsored initiatives, IDH also runs its own awareness campaigns focusing on specific diseases on a monthly basis and offering discounts on related testing

<p>IDH's PCR Offers and Campaigns</p>	 <p>صحتك وصحتهم بالدنيا..</p> <p>Discounts on PCR testing for Covid-19</p> <p>خصم يصل إلى ٢٥% على PCR و باقة عدوى فيروس كورونا للأهل و الأصحاب</p> <p>المختبر حب نفسك 19014</p>	 <p>مسافر ومحتاج تعمل تحليل PCR؟</p> <p>PCR testing for Covid-19 for people traveling</p> <p>بالتأكيد.. 19911 alborlab.com</p> <p>معامل البرج</p>
<p>IDH Disease Awareness and Discount Campaigns</p>	 <p>خلي بالك من معدتك!</p> <p>20% خصم</p> <p>20% discounts on food poisoning tests</p> <p>المختبر 19014</p>	 <p>الأنيميا والحمل</p> <p>Campaign to increase awareness on the dangers of anemia during pregnancy</p> <p>بالتأكيد.. 19911 alborlab.com</p> <p>معامل البرج</p>

Expanding Customer Reach – State-sponsored Initiatives

IDH's nationwide presence and strong brand equity position it well to benefit from state-sponsored campaigns to increase awareness of preventative healthcare with diagnostic testing

"100 Million Healthy Lives" campaign

The largest health campaign under the directive of the Egyptian President Abdel-Fattah El-Sisi, which aims to *eradicate hepatitis C across Egypt* as part of the administration's strategic 2020 plan.

The campaign also aims to *stymie the growth of chronic diseases* such as high blood pressure, diabetes and obesity, *by raising awareness on the importance of preventative healthcare with diagnostic testing.*

The campaign was launched in November 2018 and concluded in June 2019.

Duration

8mo

Nov '18 – Jun '19

Revenue Generated

EGP 84mn

Nov '18 – Jun '19

Diagnostic Testing Targeting

50mn

Citizens

Tests Completed

4.4mn

Nov '18 – Jun '19

Reach

Nationwide

Patients Served

409k

Nov '18 – Jun '19

Cost


Free for citizens

Average Revenue per Test

EGP 19

Expand Customer Reach – House Call Services

IDH's house call services, offered in both Egypt and Jordan, enable the Company to provide its services to patients' doorstep at the touch of a screen



Diversifying Service Offering – Al Borg Scan Expansion Updates

In February 2020, operations commenced at Al Borg Scan's second branch in Cairo. The Group is actively working towards obtaining ACR (American College of Radiology) accreditation for Al Borg Scan's branches, a process it expects to conclude by next year. In parallel, Al Borg Scan's third branch is expected to come online in September 2021.



Al Borg Scan draws on Al Borg's brand equity to position itself as a premium service provider offering the full range of imaging services using the latest technology and highly trained staff.

EGP 19.9 mn

1H 2021 Revenue
(+124% y-o-y)

EGP 3.1 mn

1H 2021 EBITDA
(vs EGP 0.4 mn in 1H20)

Rationale

Leverage the strong relationship between the Al Borg brand and its millions of customers while capitalizing on favorable key market dynamics.

Leadership

The business is led by a group of the nation's most prominent radiologists with a track record at Egypt's leading hospitals and radiology centres.

Near-Term Goals

Inaugurate a third branch by September 2021.


Alborg Scan Overview

Al Borg Scan offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray and mammograms.

Technology Providers



Key Services



34.3 thousand

Tests performed in 1H 2021 (+103% y-o-y)

EGP 579

1H 2021 Revenue per test (+10% y-o-y)

27.5 thousand

Patients served in 1H 2021 (+103% y-o-y)

EGP 721

1H 2021 Revenue per patient (+10% y-o-y)

Diversifying Service Offering – New Investment in Wayak

IDH launches new subsidiary “Wayak” to offer data-driven healthcare services, utilising data analytics and artificial intelligence to capitalise on IDH’s database of over c.13 million patients



Wayak Services



Medication to be hand-delivered directly to the patient



Service provider referrals to IDH’s network



Online consultations with Diagnostics reminders



Discounted services at IDH’s network of service providers, including but not limited to lab tests




Customer service and follow-up through our call center



Healthcare Records by patients’ request

Growing Geographic Footprint– Investment Rationale

IDH's regional expansion strategy targets acquisitions in African, Middle Eastern and Asian markets where it can deploy its proven business model and generate accretive value



Growing economies and strong demographics



Similar healthcare market structure to IDH's existing markets – no general practitioner and consumer-facing



Countries with stable regulatory environment




Acquisition targets must have been profitable for at least two to three years



Well-run companies with qualified management team able to deliver on strategy




Targeting majority stakes



Growing Geographic Footprint – Nigeria Expansion

In December 2017, IDH further expanded its geographical footprint with an investment in Nigeria, a value-accretive acquisition in a large, fragmented and underpenetrated diagnostic services market where our business model is well-suited to capitalise on similar healthcare and consumer trends. The Group's Nigerian operations saw EBITDA losses narrowed significantly to EGP 7 million in FY 2020 on the back of strong revenue growth for the year.

IDH entered into a strategic alliance with Man Capital LLP to form Dynasty Holding Group ("Dynasty"), which in turn partnered with the International Finance Corporation to acquire a majority stake in Eagle Eye Echo-Scan Limited ("Echo-Scan"), a medical diagnostics business based in Nigeria. The acquisition was financed through a capital increase.



Key player in Nigeria, providing quality medical diagnostic services across 12 state-of-the-art diagnostic centres in country's underserved private healthcare sector

Locations

USD 25 million will be collectively invested into Echo-Lab to expand its service offering, nationwide footprint, and improve its quality standards

USD 9.2 mn

Invested by Dynasty in
FY2018 + FY2019

USD 2.2 mn

Invested by Dynasty in
9M2020

USD 11.4 mn

Invested by Dynasty to Date

USD 1.1 mn

Invested by IFC in FY2018

USD 1.0 mn

Invested by IFC in FY2019

USD 2.1 mn

Invested by IFC to Date

Nigeria Expansion Updates

Operational progress in Nigeria expansion with existing branches being refurbished and renovated and with loss-making branches being relocated or closed. In parallel, the Group is actively seeking to optimise its offering, pushing its radiology and pathology services.

Branch Renovations & Rebranding

Rebranded the company to Echo-Lab (from Echo-Scan), which launched in November 2018 with the opening of a revamped branch reflecting its new brand and image



Headquarters moved from Abuja to Lagos

Continued roll-out of renovations / revamping plan to Echo-Lab's 12 branch locations

Closed two non-performing locations in 2018 and opened two new branches as of 30 June 2019

New C branch launched in Lagos in October 2019

Operational Milestones

Hiring new management staff
(CFO, COO, S&M Director)

Training of operational staff to improve service quality

Established new accretive deals with suppliers

Expanded test menu by sending samples
to Mega Lab in Egypt

LMS & SAP implementation

Installation of two CT and two MRI machines with commissioning started in
Lagos and Abuja

Expansion with three new Echo-Lab branches established during 2019,
bringing the total number of branches in the country to 12

Nigeria Branch Roll-Out and Renovations

Opebi Branch Renovation and Rebranding



Area 11 Branch Renovation and Rebranding



Benin Branch Renovation & Rebranding



New Victoria Island Branch



Strong Leadership & Governance



البرج
وطملمهم

برامج
الفحص
المعمل
الشاملة

البرج
Alborg

دقة نظمتك

19911
alborglab.com

f y t

Governance

A World-Class Board of Directors

The majority of members of IDH's Board of Directors are independent and offer significant experience in the healthcare market, MENA region and investment activities



Lord St John of Bletso¹
Independent Non-Executive

Lord St John has been a crossbencher in the House of Lords, UK Parliament, since 1978 and is an Extra Lord-in-Waiting to HM Queen Elizabeth II. He is currently non-executive chairman of Strand Hanson Ltd and Global Resources Investment Trust (GRIT) and serves as a director of Falcon Group and Albion Enterprise VCT. He is also a member of the advisory boards of 10Sat, Betway Group, ECO Capacity Exchange and Impala Energy. Lord St John received a BA (Law) and BSocSc (Psychology) from Cape Town University, BProc (Law) from the University of South Africa and an LLM from the LSE, London.



Prof. Dr. Hend El Sherbini
Group Chief Executive Officer

Dr. Hend has been IDH Group's Chief Executive Officer since 2012 and prior to that served as the CEO of Al Mokhtabar between 2004 and 2012. She received her MBBCh and her Master's degree in Clinical & Chemical Pathology from Cairo University in the early 1990s, and also holds a Master's degree in Public Health from Emory University in Atlanta. Dr. Hend completed her PhD in Immunology from Cairo University in 2000, where she is also a professor of clinical pathology at the university's Faculty of Medicine. She sits on the Board of American Society of Clinical Pathology (Egypt) and consults on the international certification process. Dr. Hend completed an Executive MBA from the London Business School in 2015 and was featured as Forbes most powerful women between 2016 and 2021.



Hussein Choucri^{1,2,3,4}
Independent Non-Executive
Director and Chairman of the
Remuneration Committee

Mr. Choucri is Chairman and Managing Director of HC Securities & Investment, which he established in May 1996, and he currently sits on the boards of Edita Food Industries, Six of October Development and Investment Co. (SODIC), the Holding Company for Tourism, Hotels & Cinema and the Egyptian British Business Council. Mr. Choucri served as a Managing Director of Morgan Stanley from 1987 to 1993 and served as Advisory Director at Morgan Stanley from 1993-2007. He received his Management Diploma from the American University in Cairo in 1978.



James Patrick Nolan^{2,3,4}
Independent Non-Executive
Director and Chairman of the
Audit and M&A Committees

Mr. Nolan is an Independent Director. He spent 15 years with Royal Philips NV, latterly as Head of Mergers & Acquisitions, and has also served as Head of Mergers & Acquisitions at Veon Inc., a major mobile telecoms operator in Emerging Markets. During his time at Philips, he led a series of acquisitions in diagnostic imaging, an area in which Philips is now a global leader. He has extensive quoted-company board experience having served on the boards of M*Modal Inc., Navteq Inc and SHL Telemedicine Ltd.

Mr. Nolan graduated from Oxford University in Law in 1983 and is a qualified barrister in England and Wales. He also holds an MBA from INSEAD.



Dan Olsson^{1,2,3}
Independent Non-Executive
Director

Mr. Olsson is CEO of the Team Olivia Group, a Swedish healthcare group. He has long and extensive international experience in the diagnostic sector, where he has served in a range of executive positions, among others as CEO of Unilabs Group in Geneva, Switzerland from 2007 to 2009 and has worked in the healthcare sector since 1999. Mr. Olsson studied economics at the University of Lund in Sweden.



Richard Henry Phillips
Non-Executive Director

Mr. Phillips is a founding partner of Actis LLP, the emerging markets private equity group. As Actis LLP is one of the Company's major shareholders, Mr. Phillips is not considered by the Board as being independent. He established the Actis Global Consumer Sector team and served as Head of Consumer for four years until becoming a member of the Actis Investment Committee. During the year he was responsible for the investment activity of Actis in North Africa and, latterly, Asia. Mr. Phillips is a director on the board of a number of companies including Edita Food Industries SAE, Emerging Markets Knowledge Holdings Ltd. and others. Mr. Phillips holds a degree in Economics from the University of Exeter.

¹ Nomination Committee, ² Remuneration Committee, ³ Audit Committee, ⁴ M&A Committee

Governance

IDH is committed to implementing best practices in corporate governance through the expertise of both the individual Directors and outside parties

Anti-Bribery and Anti Corruption Policy (ABAC)

The IDH Anti-Bribery and Corruption Policy requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which IDH conducts business (whether through a third party or otherwise).

No Referral Fee Policy

The practice of paying kickbacks is incompatible with the laws of most established international jurisdictions. IDH maintains a strict policy on referral fees and prohibits the payment of “commissions and financial incentives or making illegal profits” when referring patients for medical tests.

Gift Policy

IDH is committed to serving our customers and working with our partners with the highest standards of integrity. In line with this commitment, we adopt a “No Gift Policy” whereby our employees are not allowed to exchange gifts with current or potential customers, suppliers or business partners. This is to prevent any conflicts of interest, or appearance of such in our business dealings.

Internal Audit Procedures

► The Board has delegated oversight of the Group’s system of internal controls to the Audit Committee to safeguard the assets of the Group and the interests of shareholders.

► The Audit Committee reviews the effectiveness of the Group’s internal controls on an ongoing basis and reports back to the Board with their findings and recommendations.

► The Board has accordingly established that the Group has in place internal controls to manage risk including:

- the outsourcing of the internal audit function to professionals from Ernst & Young (EY) until an Internal Auditor was appointed for the Group on 16 May 2016;
- the identification and management of risk at the level of operating departments by the heads of those departments; and
- regular Board level discussion of the major business risks of the Group, together with measures being taken to contain and mitigate those risks.

While not required to comply with UK Corporate Governance Code, IDH aims to voluntarily comply with aspects of the Code while continually working toward closing the gap with premium listed entities on the London Stock Exchange. To date, the Company has established four Board committees (members on overleaf):

- 1 Nominations Committee
- 2 Remuneration Committee
- 3 Audit Committee
- 4 M&A Committee

Sustainability

Founded on the principle of providing quality medical assistance and services to better the lives of individuals and the community at large, IDH views corporate responsibility initiatives as an extension of its core purpose with the aim of improving communities in which it does business

The Moamena Kamel Foundation for Training and Skill Development

Primary Services

1

Free healthcare clinics

2

Loans for entrepreneurial women

3

Educational services for the children of Al Duweiqā community

4

Providing food for families in need of such assistance

5

Coverage of running costs for the ICU at Cairo's public-sector Kasr El Aini Hospital

IDH commits up to 1% of the net after-tax profit of its subsidiaries, Al Borg and Al Mokhtabar, to the Moamena Kamel Foundation for Training and Skill Development.

Other Corporate Responsibility Initiatives


- Services to Kasr El Aini Hospital
 - Providing medical supplies to ICU and other units
 - Providing monthly incentives for nurses at the ICU
 - Provided 12-20 beds
- Providing finance and in-kind support to El Manial Hospital
- Financial and in-kind support to Egyptians during natural disasters
- Providing Ramadan iftar (feast) meals to the underprivileged during Ramadan
- Providing free medical tests to underprivileged Egyptian children
- Sponsoring medical convoys in Fayoum



Appendix

IDH Development Story

Over 40 years of industry experience, complemented by strategic expansion to develop a strong market position across products and geographies. Today IDH has built a **scalable platform that is positioned for further strong growth**



Source: Company data

Covid-19 Internal Protocols and Preventative Measures

In light of the recent covid-19 global outbreak, IDH, in line with World Health Organization (WHO) guidelines, has implemented detailed internal protocols to guarantee the safety of its staff and patients and safeguard its operations. IDH's response to the spread of covid-19 is focused on two fronts: Staff and patient safety and business continuity.

Staff and patient safety

Appropriate Protective Equipment

All of our staff use appropriate protective equipment when interacting with patients, including those suspected of having covid-19 or any other infectious disease. We maintain a robust stock of protective equipment to ward against supply-chain risk.

Procedures for Interacting with Patients

All of our frontline staff are trained on procedures for interacting with patients suspected of carrying covid-19 or any other communicable disease. Managers regularly review these procedures with their teams and a refresher has been disseminated to all employees. These procedures include steps that are taken to (a) protect our staff and (b) protect other patients presenting at our clinics for testing.

Referring Patients Suspected of Carrying covid-19

Our team have a protocol for referring patients they suspect may carry covid-19 to the nearest state lab for testing.

Regular Communication

All members of our team are subject to regular messages reminding them that they may not report to work if they have symptoms of a covid-19 infection.

Cleaning and Disinfection

We have increased frequency of cleaning and disinfection and all facilities have been decontaminated.

Business continuity

Equipment Stock

As of date our average testing kit stock covers three months of operation (with the exception of short shelf life kits which constitute c.10% of total number of kits).

Covid-19 Testing

We are prepared with standard operating procedures for SARS CoV-2 testing in the event that we are asked by a competent health authority to participate in testing efforts.

Review of Internal Processes

We have identified head-office functions that can be performed from home and are reviewing our disaster recovery and business continuity policies to ensure that we are prepared for any eventuality.

